Biotech News

Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

Perspective Therapeutics (CATX)Perspective TherapeuticsClinical readout

Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today announced incremental data and analyses from its ongoing Phase 1/2a clinical trial of [ 212 Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). These analyses were presented today in an oral presentation at the 2026 North American Neuroendocrine Tumors Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 5-7, 2026 in Las Vegas, Nevada.

Related news

CATXPerspective Therapeutics2026-10-23 14:49 EST

Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs

CATXPerspective Therapeutics2026-11-06 17:00 EST

Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026

BMYBMYBristol-Myers Squibb Company2026-10-25 07:30 EST

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

KYMRKymera2026-10-28 20:01 EST

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

FATEFate Therapeutics2026-10-26 11:00 EST

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

ELVNEnliven Therapeutics2026-10-14 20:30 EST

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

IMCRImmunocore Holdings plc2026-11-06 17:00 EST

Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

BMYBMYBristol-Myers Squibb Company2026-10-23 14:30 EST

Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026

Perspective Therapeutics

Lead-212 Radiopharmaceuticals Perspective Therapeutics develops targeted radiopharmaceuticals using the alpha-emitting isotope lead-212. Specialized targeting molecules carry radiation to cancer cells, while related imaging agents can support patient selection and dosimetry. VMT-Alpha-NET VMT-α-NET is a lead-212 radiopharmaceutical in...

Recent company news

Stock data

Close
0.78 USD
Market cap
410.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States